Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue.
The timing of this new guidance from the Heart Rhythm Society and American College of Cardiology could not have been better—the document went live just as CMS finalized its decision to cover cardiac ablation procedures performed in ASCs.
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
The largest healthcare system in the Middle East is partnering with Nvidia to decode the human genome. If successful, the AI-heavy project will translate almost the entire language of heredity into actionable information.
Advanced Imaging Specialists, Danbury, Connecticut, alleges the breach of contract occurred shortly after it started performing services for 3 New England hospitals.
U.S. Reps. Kathy Castor, D-Fla., Brian Fitzpatrick, R-Pa., and Debbie Wasserman Schultz, D-Fla., recently reintroduced the Increasing Access to Lung Cancer Screening Act.
“Disability rights are human rights, and every policy is a disability policy issue," U.S. Rep. Ayanna Pressley, D-Mass., said in a statement after the announcement.
Smart machines have watched over the little bundle of joy practically since conception—and will be an omnipresent part of his or her life for decades to come. What can we tell this individual their life will be like?
Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue.
The timing of this new guidance from the Heart Rhythm Society and American College of Cardiology could not have been better—the document went live just as CMS finalized its decision to cover cardiac ablation procedures performed in ASCs.
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
